Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.015 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Possible lysophospholipase | 0.015 | 0.5 | 0.5 |
Trypanosoma brucei | monoglyceride lipase, putative | 0.015 | 0.5 | 0.5 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.015 | 0.5 | 0.5 |
Plasmodium falciparum | esterase, putative | 0.015 | 0.5 | 0.5 |
Mycobacterium leprae | POSSIBLE LYSOPHOSPHOLIPASE | 0.015 | 0.5 | 0.5 |
Plasmodium vivax | PST-A protein | 0.015 | 0.5 | 0.5 |
Entamoeba histolytica | hydrolase, alpha/beta fold family domain containing protein | 0.015 | 0.5 | 0.5 |
Leishmania major | monoglyceride lipase, putative | 0.015 | 0.5 | 0.5 |
Trypanosoma cruzi | monoglyceride lipase, putative | 0.015 | 0.5 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.015 | 0.5 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.015 | 0.5 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.015 | 0.5 | 0.5 |
Plasmodium falciparum | lysophospholipase, putative | 0.015 | 0.5 | 0.5 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.015 | 0.5 | 0.5 |
Mycobacterium ulcerans | lysophospholipase | 0.015 | 0.5 | 0.5 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.015 | 0.5 | 0.5 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.015 | 0.5 | 0.5 |
Plasmodium falciparum | lysophospholipase, putative | 0.015 | 0.5 | 0.5 |
Trichomonas vaginalis | valacyclovir hydrolase, putative | 0.015 | 0.5 | 0.5 |
Plasmodium falciparum | lysophospholipase, putative | 0.015 | 0.5 | 0.5 |
Trypanosoma brucei | monoglyceride lipase, putative | 0.015 | 0.5 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.